How do you justify adjuvant radiotherapy in pancreatic cancer?

I can't convince the surgeons to refer their patients for adjuvant RT because the prospective data is messy and doesn’t seem to indicate a benefit. The best median survival in the retrospective studies is similar to that in the prospective chemotherapy alone studies (20-23 months).

Answer from: Radiation Oncologist at Academic Institution

Even though it was flawed in every imaginal way, ESPAC1 had a high impact and made post-op chemoradiation experimental. Prior to that, radiation was not based on very much evidence. GITSG was a 40-patient positive study; the EORTC trial was negative. After the ESPAC1, the focus shifted to neoadjuvan...

Comments

Radiation Oncologist at Texas Oncology-Arlington Cancer Center North
When treating adjuvantly for positive margin, do y...

Radiation Oncologist at Memorial Sloan-Kettering Cancer Center
I only use respiratory motion management when ther...

Answer from: Radiation Oncologist at Academic Institution

In terms of randomized data, the only positive trial is GITSG. This is so small, accrued over such a long time, and was done such a long time ago, that it cannot be considered compelling evidence for treatment. The EORTC trial had similar results to GITSG, but the results did not reach statistical ...

Please select the option that best describes you:

How do you justify adjuvant radiotherapy in pancreatic cancer?

Related Questions